AI drug discovery company

Enveda

Data as of Oct 17, 2026.

Company facts

Founded

2019

ReportedSource for founded (opens in new tab)
Headquarters

United States (Boulder, CO)

ConfirmedSource for headquarters (opens in new tab)
Total funding

$845M

ConfirmedSource for total funding (opens in new tab)

Latest funding round

Round: Series E
Date: Sep 23, 2026
Amount: $311M
Lead investor: Catalio Capital Management

ConfirmedSource for the latest round (opens in new tab)

Drugs on the board

ENV-294

Phase 2 registry

Atopic dermatitis; asthma

Registry for ENV-294 (opens in new tab)
ENV-308

Phase 1 per company

Metabolic health, weight maintenance after GLP-1 treatment

Source for ENV-308 (opens in new tab)

Recent news

Sep 29, 2026

EADV 2026 late-breaker mechanistic and biomarker data for ENV-294 in atopic dermatitis and asthma

ConfirmedSource (opens in new tab)
Sep 23, 2026

Announced $311M Series E (official)

ConfirmedSource (opens in new tab)
Aug 18, 2026

ENV-308 allowed Phase 1, second clinical-stage molecule to do so

ConfirmedSource (opens in new tab)
Dec 23, 2025

Second IND; Phase 1 started for ENV-6946 (three first-in-class clinical programs)

ConfirmedSource (opens in new tab)
Dec 17, 2025

FDA IND and first patient dosed for ENV-308

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.